
Meta-Analysis: GnRH Analog Preserves Ovarian Function in Early Breast Cancer
This video reviews a meta-analysis that looked at five studies testing the use of a gonadotropin-releasing hormone (GnRH) analog to protect ovarian function and preserve fertility in premenopausal women undergoing chemotherapy for early-stage breast cancer.
In this video, Halle C. F. Moore, MD, of the Cleveland Clinic in Ohio, discusses a meta-analysis that looked at five studies testing the use of a gonadotropin-releasing hormone (GnRH) analog to protect ovarian function and preserve fertility in premenopausal women undergoing chemotherapy for early-stage breast cancer.
Moore was one of the authors of the study (
Related to this article


!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)





